- Home
- GILD vs UL Comparison
GILD vs UL Comparison
Compare GILD & UL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | UL |
|---|---|---|
| Founded | 1987 | 1930 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.9B | 153.0B |
| IPO Year | 1992 | N/A |
Fundamental Metrics
Financial Performance| Metric | GILD | UL |
|---|---|---|
| Price | $154.98 | $74.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 18 | 0 |
| Target Price | ★ $141.56 | N/A |
| AVG Volume (30 Days) | ★ 8.8M | 3.9M |
| Earning Date | 02-10-2026 | 03-12-2026 |
| Dividend Yield | 2.12% | ★ 3.04% |
| EPS Growth | ★ 1684.21 | 38.61 |
| EPS | ★ 6.78 | 5.07 |
| Revenue | $29,443,000,000.00 | ★ $59,296,700,739.00 |
| Revenue This Year | $4.68 | N/A |
| Revenue Next Year | $5.11 | N/A |
| P/E Ratio | $22.86 | ★ $14.77 |
| Revenue Growth | ★ 2.40 | N/A |
| 52 Week Low | $93.37 | $61.11 |
| 52 Week High | $157.29 | $74.98 |
Technical Indicators
Market Signals| Indicator | GILD | UL |
|---|---|---|
| Relative Strength Index (RSI) | 70.71 | 79.32 |
| Support Level | $147.00 | $71.45 |
| Resistance Level | $157.29 | $72.16 |
| Average True Range (ATR) | 4.28 | 1.01 |
| MACD | 0.86 | 0.48 |
| Stochastic Oscillator | 88.30 | 95.56 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About UL Unilever PLC
Unilever is a diversified beauty, wellbeing, and personal care (44% of 2024 sales by value), homecare (20%), and packaged food (36%) company. Its brands include Dove personal-care products, Knorr soups and sauces, Hellmann's mayonnaise, Axe and Rexona deodorants, and TRESemmé haircare. The firm has been acquisitive in recent years; notable purchases include Paula's Choice, Liquid I.V., Horlicks, and Wild deodorants. The company derives 58% of its sales from emerging markets and 42% from developed markets. The US is its largest market, accounting for around 20% of sales, followed by India, which accounts for 11% of sales.